Are antibodies to adalimumab associated with future inflammation in Crohn 's patients receiving maintenance adalimumab therapy : a post hoc analysis of the Karmiris trial?
ATA were detected in 20% of patients. Risk of ATA formation increased with lower early serum ADL concentration and in patients not on IMM. ATA and ADL were strongly associated with higher future CRP level and discontinuation of ADL.
In contrast to rodent models, CGL patients have increased BMC in the leptin-deficient state, which does not change with leptin replacement. The high BMC in these patients is partially explained by high lean mass and tall stature.